New Delhi: Drug firms Aurobindo Pharma and Glenmark today said they have received approval from the US health regulator to manufacture and market generic montelukast sodium tablets used for treating asthma and allergies. Both the companies said they would immediately commence distribution of the product in the US market. Quoting IMS health data, they said the annual sales of montelukast sodium tablets 10 mg were nearly USD 3.5 billion and that of chewable tablets is USD 1.1 billion for the twelve months ending March 2012. In a statement Aurobindo Pharma said: "The company has received final approval from the USFDA to manufacture and market montelukast sodium tablets 10mg and montelukast sodium chewable tablets 4mg and 5mg."
Flightless molecule can prevent cancer from spreading
Pupil dilation can disclose sexual orientation: Study